

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research











